Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control (opens original article in a new tab)

Crinetics presented long-term data showing PALSONIFY effectively controls acromegaly with stable IGF-1 levels and symptoms over two years, and may reduce tumor volumes.

• PALSONIFY maintained lower IGF-1 levels and stable symptoms for up to two years in acromegaly patients
• Treatment showed stable or reduced pituitary tumor volumes in some patients
• Combination with cabergoline improved biochemical control of acromegaly